-
Mashup Score: 9
Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely be cured. Eradication of minimal residual disease (per ctDNA clearance) with chemotherapy did not occur in most ctDNA-positive patients and led to eventual disease relapse. See related article by Henriksen et al.,…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The coronavirus disease 2019 (COVID-19), now entering its third year, has led to major disruptions to economic stability, health care, and scientific research across the globe. To address the negative impact of COVID-19 on the cancer care continuum as well as the broader interruptions caused by the
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/KteLsDokN8 https://t.co/pNuEVSJpoP
-
#ICYMI: Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/IhJxKp9fdZ https://t.co/oLCVbSlVZm
-
#ICYMI: Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/Qvhdb0aNeT https://t.co/E0bS68VOXb
-
#ICYMI: Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/cKM9FWLNzx https://t.co/Kbg9OPilWE
-
-
Mashup Score: 3Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors - 2 year(s) ago
Purpose: Entrectinib potently inhibits TRKA/B/C and ROS1, and previously induced deep (objective response rate [ORR] 57.4%) and durable (median duration of response [DoR] 10.4 months) responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This manuscript expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Entrectinib in Pts with NTRK+ Solid Tumors: - 121 pts with 14 diff tumor types - ORR: 61.2% - mDoR: 20.0mo - intracranial ORR: 63.6% - 8.3% pts stopped Tx for TRAEs Grateful to see multiple agents targeting #NTRK, the golden needle @OncoAlert https://t.co/PCVp7Pgv6s
-
-
Mashup Score: 1Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis - 2 year(s) ago
Purpose: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or refute diagnosis. Further, there is no quantitative response tool to assess response or progression during BCLM treatment. Experimental Design: Facing the challenge of working…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
CSF ctDNA in Leptomeningeal Dx from breast cancer: - ctDNA detected in all 24pts BCLM+ - ⬇️ctDNA on IT tx assoc with BCLM OS -⬆️ctDNA pre progressn Analysis reminiscent of our paper in pts with LM from solid tumors tx’d with Pembro @jitcancer https://t.co/FNaUa7dQEC
-
-
Mashup Score: 2Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) - 2 year(s) ago
Purpose: Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and future molecularly targeted therapies. Patients and Methods: An investigational clinical trial assay, based on the FoundationOne®CDx tissue test, was used to prospectively identify patients with…
Source: Clinical Cancer ResearchCategories: Latest Headlines, UrologyTweet-
Results from the Phase III Trial PROfound published in @CCR_AACR demonstrate the feasibility of tissue testing to identify alterations in DNA-repair genes and stratify patients with mCRPC to receive olaparib https://t.co/CBmHVsBCAe
-
-
Mashup Score: 1A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors - 2 year(s) ago
Purpose: Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the oral, first-in-class, glutaminase (GLS) inhibitor telaglenastat was conducted in treatment-refractory solid tumor patients to define recommended phase II dose (RP2D) and evaluate safety, pharmacokinetics (PK), pharmacodynamics…
Source: Clinical Cancer ResearchCategories: Latest Headlines, Oncologists1Tweet-
SCI leader @melindatelli and colleagues conducted a #phase1 dose-escalation and expansion study of telaglenastat, an oral, first-in-class, glutaminase (GLS) inhibitor, in patients with advanced or metastatic solid tumors. #clinicaltrial #metastaticcancer https://t.co/34KsSfbSbz
-
-
Mashup Score: 5Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors - 2 year(s) ago
Purpose: Entrectinib potently inhibits TRKA/B/C and ROS1, and previously induced deep (objective response rate [ORR] 57.4%) and durable (median duration of response [DoR] 10.4 months) responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This manuscript expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors | Clinical Cancer Research https://t.co/AO8aLbhVVq
-
🚨Updated Integrated Analysis of the Efficacy+ Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors ➡️121 adults, 14 tumor types ✅ORR =61.2% @CCR_AACR #PrecisionMedicine @DrSarcoma @ChristianRolfo @OncoAlert https://t.co/flr1aTTjjH https://t.co/HjTsNzSx5Q
-
-
Mashup Score: 2
The coronavirus disease 2019 (COVID-19), now entering its third year, has led to major disruptions to economic stability, health care, and scientific research across the globe. To address the negative impact of COVID-19 on the cancer care continuum as well as the broader interruptions caused by the
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/cKM9FWLNzx https://t.co/AkuUNBMlao
-
Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/Qvhdb0aNeT https://t.co/dKejKj9VoP
-
Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/KteLsDokN8 https://t.co/0HZo6NBGOi
-
Special Report: AACR Report on the Impact of #COVID-19 on Cancer Research and Patient Care. https://t.co/IhJxKp9fdZ https://t.co/LVVmhan8iH
-
-
Mashup Score: 2Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics - 2 year(s) ago
Purpose: Cyclin and MAPK/MEK-related gene alterations are implicated in cell-cycle progression and cancer growth. Yet, monotherapy to target the cyclin (CDK4/6) or the MEK pathway has often yielded disappointing results. Because coalterations in cyclin and MEK pathway genes frequently cooccur, we hypothesized that resistance to CDK4/6 or MEK inhibitor monotherapy might be mediated via activation…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/COUfabXmnr
-
-
Mashup Score: 0
The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations. See related article by Kato et al., [p. 2792][1] …
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game @CCR_AACR @OncoAlert https://t.co/QQ1D6ceflp
-
RT @CCR_AACR: Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be? https://t.co/fEPkzcAB7H https://t.co/s7JHE…